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Intellectual disability (ID) or mental retardation or learning 
disability is a lifelong condition included in the group of men-
tal disorders in all the international classification systems. It is 
a syndrome grouping (meta-syndrome) including a heteroge-
neous range of clinical conditions characterized by a deficit in 
cognitive functioning prior to the acquisition of skills through 
learning (1). Over 30% of people with ID have a comorbid 
psychiatric disorder, which often has its onset in childhood 
and persists through adolescence and adulthood (2,3). 
In spite of this evidence, ID and related conditions are 
still considered a marginal area of psychiatry. In many coun-
tries there is little or no training provision on ID during un-
dergraduate medical training or psychiatric specialization. 
The World Health Organization (WHO) has recently high-
lighted the unmet care needs of persons with ID (4). Psy-
chiatrists are the first health professionals in contact with 
this population group and there is a global gap in training 
and guidelines on mental health issues related to ID.
Within the ID field, the assessment, differential diagnosis 
and treatment of problem behaviours (PBs) deserve special 
attention. The rate of PBs in people with ID is high (5) and 
their presentation is determined by many complex factors. 
The pathogenic contribution of organic conditions, psychiat-
ric disorders, environmental influences, or a combination of 
these has to be carefully established for every single case.
The prevalence of PBs in people with ID seems to be suf-
ficiently high (5,6) to constitute a major concern in this 
population. Depending on the definition and methodology, 
rates have been reported to vary from 5.7 to 17% (7-10). 
Using the Diagnostic Criteria for Psychiatric Disorders for 
Use with Adults with Learning Disabilities (DC-LD) (11), 
Cooper et al (12,13) recently found the point prevalence of 
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aggression and self-injurious behaviour to be 9.8% and 
4.9%, respectively, among adults (16 years and over) with ID 
in a community setting.
It has been reported that 20-45% of people with ID are 
receiving psychotropic medication and 14-30% are receiving 
psychotropic medication to manage PBs such as aggression 
or self-injurious behaviours (14,15) in the absence of a diag-
nosed psychiatric disorder. Examples of psychotropic medi-
cations used for adults with ID are antipsychotics, antide-
pressants, anti-anxiety drugs (benzodiazepines, buspirone, 
beta-blockers), mood stabilizers (lithium, anticonvulsants), 
psychostimulants, and opioid antagonists. Spreat et al (16) 
reported that as many as two thirds of psychotropic medica-
tions prescribed to people with ID are antipsychotics.
Studies suggest that PBs are not only prevalent but also 
persistent in people with ID (17-19). Totsika et al (20) found 
that serious physical attacks, self-injury and stereotypy were 
the most likely types of PBs to persist over time. It is there-
fore suggested that it may be necessary to start interventions 
as early as possible to prevent the behaviours from becoming 
more serious and to reduce the number of emergent behav-
iours. It has been pointed out that many of the behaviours 
that emerge are a direct consequence of limitations in peo-
ple’s ability to communicate effectively (21-25). Replacing 
“learned behaviour” at an early age with more acceptable 
forms of communication may therefore not only reduce the 
number of emerging behaviours, but also reduce the severity 
of the behaviours that do occur. 
The rate of prescription of psychotropic medications for 
the management of PBs is a source of concern, due to the 
scarce evidence concerning their effectiveness and adverse 
events and their impact on quality of life in people with ID 
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(14,26-29). Many adults with ID receive multiple psychotro-
pic medications and in high dose. 
The InTernaTIonal guIde 
Framework and development
The international guide is an adaptation from the recent-
ly developed guide on the subject (30) in the UK. The UK 
guide followed the NICE guideline development procedure. 
This includes a systematic review of evidence and a broad 
consensus based on the available evidence on good practice. 
A very extensive stakeholder consultation was carried out 
before finalizing the recommendations.
The international guide reflects the available knowledge 
and the perspectives of experts practicing in psychiatry of ID 
in different parts of the world. A PB is defined here as a 
“socially unacceptable behaviour that causes distress, harm 
or disadvantage to the persons themselves or to other peo-
ple, and usually requires some intervention” (30). The guide 
neither supports nor refutes the use of psychotropic medica-
tions in this context, but provides clinicians and carers of 
adults with ID worldwide with good practice advice despite 
the lack of adequate good quality evidence on this subject. 
The main recommendations contained in the guide are sum-
marized in the following sections.
assessment and formulation
The primary aim of management of PBs in people with ID 
should be not to treat the behaviour per se but to identify and 
address the underlying cause of the behaviour. However, it is 
not always possible to find a cause for the PB. When a cause 
cannot be found, the management strategy should be to min-
imise the impact of the behaviour on the person, the environ-
ment around her/him and other people.
There may be many reasons for PBs, including physical 
or mental health problems. Many factors, internal (e.g., neg-
ative childhood experiences, maladaptive coping strategies) 
or external to the person (e.g., an under-stimulating or over-
stimulating environment), may contribute to PBs. Some-
times behaviour may be used as a means of communication. 
For example, persons with severe ID who cannot speak or 
use a sign language may scream because they are in pain and 
they cannot communicate this message in any other way. 
Sometimes persons with ID may use behaviour to commu-
nicate their likes and dislikes. 
Therefore, a thorough assessment of the causes of behav-
iour and their consequences, along with a formulation, is an 
absolute prerequisite in managing any PB. A comprehensive 
assessment may require input from several disciplines and 
from families and carers. It should cover personal, psycho-
logical, social, environmental, medical and psychiatric issues. 
A multi-axial/multilayered diagnostic formulation, such as 
that suggested in the DC-LD (11) and the Diagnostic Manu-
al – Intellectual Disability (DM-ID) (31), may be useful in this 
context. A formulation should be made even in the absence 
of a medical or psychiatric diagnosis. 
As a general rule, the formulation should consist of the 
following:
– A list of the target PB(s) to be managed.
– A clear description of the PB, including frequency and 
severity.
– An assessment of causes giving rise to the PB.
– A record of reactions to and outcomes of the behaviour.
– An evaluation of predisposing, precipitating and perpetu-
ating risk factors.
– Consideration of all management options and their out-
come.
– The rationale for the proposed management option.
– A risk assessment for all the involved parties.
– Possible benefits and adverse effects from the proposed 
intervention(s).
– The likely effect of the proposed intervention(s) on the 
person’s and her/his family’s quality of life.
A proper assessment and formulation will often depend 
on input from the person with ID and/or her/his family and 
carers. This input should continue at every stage of manage-
ment. It is important to share information with the person 
with ID in a way that he/she can understand. This may re-
quire additional time and effort on the part of the health 
professionals and other members of the multidisciplinary 
team. It may also involve using other methods of informa-
tion sharing, such as pictures. 
Multidisciplinary input may also be needed during imple-
mentation and monitoring of the management options. This 
may not always be possible to achieve, because of lack of 
resources or expertise in this field. Where relevant and if 
possible, an attempt should be made to secure multidisci-
plinary input throughout the process of assessment and 
management.
When to consider medication
If there is an obvious physical or psychiatric cause for the 
behaviour, this should be managed appropriately. The relevant 
guides governing the use of medication in the treatment of the 
particular psychiatric disorder should be followed (32,33).
If no treatable physical or psychiatric disorder can be rec-
ognized, then non-medication based management such as 
behavioural strategies should be considered first. Sometimes, 
after considering non-medication based management op-
tions, medication may be needed either on its own or as an 
adjunct to non-medication based management. However, it 
may also be possible to improve the PB of the person by pro-
viding counselling or addressing some adverse social and en-
vironmental factors, for example by finding more enjoyable 
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activities to do during the day, and using medication simulta-
neously to make the person concerned less anxious. This may 
be seen as an interim strategy, which then needs to be moni-
tored carefully at regular intervals to assess its effectiveness.
The exact situation under which medication and/or non-
medication based management strategies should be imple-
mented will depend on individual circumstances. Below are 
some of the situations under which the clinicians may con-
sider using medication:
– Failure of non-medication based interventions.
– Risk/evidence of harm/distress to self.
– Risk/evidence of harm/distress to others or property.
– High frequency/severity of PB.
– To treat an underlying psychiatric disorder or anxiety.
– To calm the person to enable implementation of non-
medication based interventions.
– Risk of breakdown to the person’s placement.
– Good previous response to medication.
– Person/carer choice. 
The lack of adequate or available non-medication based 
interventions should not be the only reason for using medi-
cation, although in practice this may happen. Under such 
circumstances, the medication should be used for as short a 
period as possible. 
The management of PB should always be person-centred. 
The plan should be discussed with the person with ID and/
or her/his carers and should be designed according to the 
person’s best interests. The prescribing should not take place 
in isolation but should always be part of a much broader 
person-centred care plan. 
Monitoring the effectiveness of medication
The effectiveness and possible adverse effects of the pre-
scribed medication should be monitored at regular intervals. 
This should include collecting objective information from 
family members, carers, staff of the multi-disciplinary team 
as well as the person with ID, where necessary and possible. 
Physical examination and relevant investigations such as 
blood tests and ECG/EKG should also be performed when 
necessary.
The medication should be prescribed at the lowest pos-
sible dose and for the minimum duration. Non-medication 
based management strategies and the withdrawal of medica-
tion should always be considered at regular intervals. If the 
improvement of the PB is unsatisfactory, an attempt should 
be made to revisit and re-evaluate the formulation and the 
management plan.
Communication issues
The management plan should be communicated clearly 
to the person with ID and/or her/his family and carers and 
all other relevant professionals involved on a need-to-know 
basis. This process should be updated at regular intervals. 
Accessible format may be needed when communicating 
with adults with ID. The prescribing should be carried out 
according to the country’s legal framework and clearly doc-
umented in medical records.
In Figure 1 we present a flow chart summarising the main 
activities involved in the process of prescribing and monitor-
ing of its effect.
general principles for prescribing psychotropic  
medications
Anyone prescribing medication to manage PBs in adults 
with ID should keep the following good practice points in 
mind:
– Medication should be used only in the best interests of 
the person.
– All non-medication management options should be con-
sidered, and medication should be seen as necessary under 
the circumstances, or alongside non-medication manage-
ment.
– If possible, evidence to show that the medication is cost-
effective should be taken into account.
– Information about which medications worked before and 
which did not should be noted.
– If medication used previously produced unacceptable ad-
verse effects, the details should be noted.
– The effect of availability or non-availability of certain ser-
vices and therapies on the treatment plan should be taken 
into account.
– Relevant local and national protocols and guidelines 
should be followed.
Once the decision to prescribe is taken, the following 
points should be followed:
– Ensure that the appropriate physical examinations and 
laboratory investigations are carried out at regular inter-
vals.
– Explain to the person and/or her/his family or carers if 
the medication is being used outside its licensed indica-
tions. In this case, they should be told about the evidence 
that is available to demonstrate its effectiveness.
– Identify a key person who will ensure that medication is 
administered appropriately and communicate all changes 
to the relevant parties.
– If possible, provide the person and/or her/his family or 
carers with a copy of the agreed recommended treatment 
plan at the time of prescribing. 
– As far as possible, there should be an objective way to 
assess outcomes, including adverse effects (where possi-
ble the use of standardized scales or the monitoring of the 
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severity and frequency of the target behaviour is recom-
mended) (34). 
– Ensure there will be follow-up assessments for continued 
monitoring.
– As far as possible, one medication for the PB should be 
prescribed at a time.
– As a general rule, the medication should be used within 
the standard recommended dose range.
– A dose of medication above the maximum recommended 
should only be used in exceptional circumstances after 
full discussion with all the relevant stakeholders under 
appropriate safeguards and regular reviews.
– Start with a low dose and titrate the dose up slowly.
– Medication should be used at the lowest required dose for 
the minimum period of time necessary.
– Consideration for withdrawing medication and exploring 
non-medication management options should be ongoing.
Currently, it is not possible to recommend the type of 
medication for the treatment of specific PBs because there 
is no evidence to support such specificity (35).
risks associated with prescribing medication
in adults with Id and PB
Most medications carry a potential risk associated with 
adverse events. However, evidence is largely gathered from 
studies among patients who do not have ID. For example, 
current evidence shows that several newer antipsychotic 
medications may produce weight gain and some metabolic 
abnormalities related to glucose tolerance, lipid metabolism 
and prolactin secretion (36).
There is no good-quality evidence to either support or 
refute concerns that people with ID may be at greater risk 
of the adverse effects of medication than people from the 
general population who do not have ID. The shortage of 
good-quality evidence does not mean that medication is 
associated with an unacceptable risk specifically for adults 
with ID. 
In view of the above, the following general points should 
be kept in mind:
– Discuss with the person and/or her/his family or carers 
about both common and serious adverse events related to 
the medication (where possible provide accessible infor-
mation in writing). 
– Advise what action should be taken if a serious adverse 
event occurs.
– All adverse events should be recorded properly.
– Once a medication is prescribed, the risk-benefit profile 
should be evaluated regularly, with particular emphasis on 
the person’s and her/his family or carers’ quality of life.
Figure 1  Key processes associated with using medication to manage problem behaviours in adults with intellectual disability
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Withdrawing medication that has been prescribed  
for a long period
Studies of withdrawing medication show that, in some 
people with ID, the medication can be successfully with-
drawn after a long period of use (37,38). In another group, 
the dose can be reduced, but total withdrawal is not possi-
ble. Lastly, there remain certain cases where medications 
cannot be reduced even after a very long period of use. Many 
factors affect the success of withdrawal of medication, in-
cluding social and environmental factors such as the train-
ing and the attitude of care staff. However, on the basis of 
such evidence, it is not possible to recommend which med-
ication to withdraw and the rate of withdrawal, but the fol-
lowing general recommendations are proposed:
– Try to stabilise the person’s PB on a minimum number of 
medications prescribed at the lowest possible dose.
– Withdraw one medication at a time.
– Withdraw medication slowly.
– If necessary, allow time (sometimes a few weeks) after 
withdrawing one medication and before starting to with-
draw another.
FuTure dIreCTIons
There are plans to publish this guide in other languages 
as it has been done with previous guides produced by the 
WPA Section on Psychiatry of Intellectual Disabilities. 
Spanish and Italian translations will be available this year. 
The Section also plans to develop training materials on as-
sessment of PBs among adults with ID, and to enhance links 
with other international organizations on this topic.
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